Gerstein HC, et al. - Via conducting an exploratory analysis of REWIND—a multicenter, randomized, double-blind, placebo-controlled trial carried that included 9,901 participants—researchers assessed the long-term effect of dulaglutide on renal outcomes and on cardiovascular disease. Urinary albumin-to-creatinine ratios and estimated glomerular filtration (eGFR) rates were evaluated from urine and serum values measured in local laboratories. Patients with new macroalbuminuria, sustained decline in eGFR, and chronic renal replacement therapy demonstrated the clearest effects. Overall, in people with type 2 diabetes, long-term use of dulaglutide was linked to reduced composite renal outcomes.